What is Protagonist Therapeutics Inc (PTGX) stock price today?

Protagonist Therapeutics Inc (PTGX) currently trades at $98.97 per share. The stock has a market capitalization of $6.34B and a P/E ratio of —x.

Is PTGX stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Protagonist Therapeutics Inc has a Smart Value Score of 28/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Protagonist Therapeutics Inc's revenue and earnings?

Protagonist Therapeutics Inc has trailing twelve-month (TTM) revenue of $46.02M with profit margins of -282.80%. Earnings per share (EPS) is $-2.05.

PTGX

Protagonist Therapeutics Inc

NASDAQ: PTGX · HEALTHCARE · BIOTECHNOLOGY

$98.97

+0.46% today

Updated 2026-04-30

Market cap

$6.34B

P/E ratio

—

P/S ratio

137.68x

EPS (TTM)

$-2.05

Dividend yield

—

52W range

$41 – $108

Volume

0.8M

Market cap

$6.34B

P/E ratio

—

P/S ratio

137.68x

EPS (TTM)

$-2.05

Dividend yield

—

52W range

$41 – $108

Volume

0.8M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

7.3

Growth

B+

5.0

Quality

C+

2.0

Profitability

5.0

Valuation

C+

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$113.33

+14.51%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

3 Strong Buy8 Buy1 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

Insufficient data

Risks

- Thin margins at -282.80%

- Negative free cash flow $-38.42M

- Revenue declining -95.60% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$26.58M	$60.00M	$434.43M	$46.02M	$46.02M
Net income	$-123.41M	$-78.95M	$275.19M	$-130.15M	$-44.38M
EPS	—	—	—	—	$-2.05
Free cash flow	$-108.93M	$-70.84M	$182.80M	$56.08M	$-38.42M
Profit margin	-464.29%	-131.59%	63.34%	-282.83%	-282.80%

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
PTGX	$6.34B	28	7.3	2.0	5.0	5.0	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Protagonist Therapeutics Inc trades at $98.97. Our Smart Value Score of 28/100 indicates the stock is weak. TTM revenue stands at $46.02M. with profit margins at -282.80%.

Frequently asked questions

What is Protagonist Therapeutics Inc's stock price?

Protagonist Therapeutics Inc (PTGX) trades at $98.97.

Is Protagonist Therapeutics Inc overvalued?

Smart Value Score 28/100 (Grade F, Strong Sell).

What is the price target of Protagonist Therapeutics Inc (PTGX)?

The analyst target price is $113.33, representing +14.5% upside from the current price of $98.97.

What is Protagonist Therapeutics Inc's revenue?

TTM revenue is $46.02M.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio137.68x

ROE-20.20%

Beta2.11

50D MA$97.76

200D MA$79.33

Shares out0.06B

Float0.05B

Short ratio—

Avg volume0.8M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

PTGX vs LLY →PTGX vs JNJ →PTGX vs ABBV →Stock screener →